SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02043223

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Stopping Postpartum Vitamin A Supplementation: Are we Missing Concealed Benefit?

The purpose of this study is to evaluate the effect of post-partum maternal vitamin A supplementation on breast milk bioactive compounds and immune status, growth and morbidity of children in the first four months of life.

NCT02043223 Vitamin A Deficiency
MeSH: Vitamin A Deficiency Night Blindness
HPO: Low levels of vitamin A Nyctalopia

4 Interventions

Name: Vitamin A (<3-day postpartum)

Description: Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.

Type: Dietary Supplement

Early postpartum vitamin A suppl.

Name: Vitamin A (6 wk postpartum)

Description: Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.

Type: Dietary Supplement

Late postpartum vitamin A suppl.

Name: Vitamin A (<3-day and 6 wk postpartum)

Description: 200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum

Type: Dietary Supplement

Early Early & Early & late postpartum vitamin A suppl

Name: Placebo

Description: Placebo supplementation, both at <3-day and 6-wk postpartum.

Type: Dietary Supplement

No postpartum vitamin A suppl.


Primary Outcomes

Description: immune regulators in breast milk e.g. B-cell activating factor (BAFF); IL-7; Lactoferrin; sCD14, sIgA and TGF-beta levels at three time points- < 3-day postpartum (before 1st dose of supplementation) 7 wk postpartum (1wk after 2nd dose of supplementation) 15 wk postpartum

Measure: Breast milk immune regulators

Time: Four months

Secondary Outcomes

Description: Mitogen stimulated whole blood IL-10, IL-13, IFN-gamma, IL-21 and IL-17 responses at two time points- 7 wk of age (1wk after 2nd dose of maternal supplementation , as well as, 1wk after first doses of pentavalent vaccination) 15 wk of age (1wk after three doses of pentavalent vaccination)

Measure: Infant T helper cell immune responses

Time: Four months

Description: Tall like receptor (TLR)-4 and TLR9 agonist stimulated whole blood TNF-alpha and IL-10 and IFN-alpha responses at two time points- 7 wk of age (1wk after 2nd dose of maternal supplementation , as well as, 1wk after first doses of pentavalent vaccination) 15 wk of age (1wk after three doses of pentavalent vaccination)

Measure: Infant innate immune responses

Time: Four months

Description: Hepatitis B and Tetanus Toxoid specific plasma cell IgG responses at 15 wk of age (1wk after three doses of pentavalent vaccination) And Hepatitis B and Tetanus Toxoid specific IgG in plasma and Polio (3 serotypes) specific secretory IgA (sIgA) in stool at two time points- 7 wk of age (1wk after 2nd dose of maternal supplementation , as well as, 1wk after first doses of pentavalent vaccination) 15 wk of age (1wk after three doses of pentavalent vaccination)

Measure: Infant vaccines (Hepatitis B, Tetanus and Oral polio) specific antibody responses

Time: Four months

Description: Next generation sequencing (NGS) of bacterial 16s rDNA (+qPCR) in extracted stool samples and assessment of infant gut inflammatory markers e.g. human β-defensin-2 (HBD2); Neopterin; α-1-antitrypsin (AAT); neutrophil gelatinase-associated lipocalin (NGAL)-2 and S100A at two time points- 7 wk of age (1wk after 2nd dose of maternal supplementation , as well as, 1wk after first doses of pentavalent vaccination) 15 wk of age (1wk after three doses of pentavalent vaccination)

Measure: Relative abundance of infant gut microbial community and gut inflammatory markers

Time: Four months

Other Outcomes

Description: Infant plasma vitamin A status at 7 wk and 15 wk of age

Measure: Infant vitamin A status

Time: Four months

Description: Infant Weight-for-Age z-score (WAZ) at 7 wk and 15 wk of age

Measure: Infant growth

Time: Four months

Description: Infant morbidity status up to four months of age

Measure: Infant morbidity

Time: Four months

Description: Plasma Retinol Binding Protein (RBP) and breast milk vitamin A level at two time points- < 3-day postpartum (before 1st dose of supplementation) 15 wk postpartum

Measure: Mother vitamin A status

Time: Four months

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 S100A

human β-defensin-2 (HBD2); Neopterin; α-1-antitrypsin (AAT); neutrophil gelatinase-associated lipocalin (NGAL)-2 and S100A at two time points- 7 wk of age (1wk after 2nd dose of maternal supplementation , as well as, 1wk after first doses of pentavalent vaccination) 15 wk of age (1wk after three doses of pentavalent vaccination). --- S100A ---



HPO Nodes


HPO:
Low levels of vitamin A
Genes 5
MST1 FARSB GPR35 TCF4 BCO1
Nyctalopia
Genes 186
SPATA7 CYP4V2 WHRN CERKL RPGRIP1 PRPF31 CACNA1F PCYT1A LRAT IFT140 BEST1 ARL2BP NR2E3 MAK CIB2 AHI1 ABCA4 PDE6A HK1 PDE6G PDE6H IMPDH1 OFD1 NMNAT1 NRL MYO6 PDE6B MYO7A IFT172 KCNV2 KIZ ADAM9 CDHR1 TTLL5 FLVCR1 PEX3 DHX38 RBP3 HGSNAT OPN1LW PEX1 KIAA1549 PEX6 BBS2 PEX7 RDH5 PEX10 RDH12 POMGNT1 CDH23 BBS4 PEX12 PRPH2 PEX13 DHDDS ARHGEF18 PEX14 PCARE OAT POU3F4 PDZD7 DRAM2 PRPF6 ADGRV1 NYX OPN1MW IDH3B AGBL5 PEX11B CHM MFRP PRPF8 USH1C GRM6 RAX2 TTPA RGR TUB LRIT3 SLC7A14 GGCX GPR179 ARSG PEX26 TULP1 RHO CRB1 GRK1 CRX RLBP1 ELOVL4 STIM1 ARL6 UNC119 CNNM4 TTC8 PROM1 ATF6 NEK2 HSD3B7 PHYH EYS ARL3 RAB28 CACNA2D4 TRNT1 SAG COX1 COX2 CEP78 GUCA1A COX3 GUCA1B IFT88 KLHL7 PRPF4 PRPF3 REEP6 FAM161A USH1G CABP4 ZNF408 ND1 GUCY2D KCNJ13 ND4 CNGB3 ND5 POC1B ND6 SCAPER PEX19 PEX16 PCDH15 FSCN2 AIPL1 PITPNM3 AHR PEX2 PRCD PEX5 MFN2 TRNF ROM1 TRPM1 TRNH RP9 RP1 HADHA RP2 C1QTNF5 FGFR2 TRNL1 RPGR RIMS1 SEMA4A C8ORF37 GNAT1 HARS TRNQ MERTK TRNS1 TRNS2 GNB3 TOPORS TRNW SLC24A1 HBB ITM2B MMP19 USH2A RPE65 CLRN1 CNGB1 CNGA1 SNRNP200 CNGA3 AP3D1 COG4 TRAPPC9 VPS13B CFAP410 MVK CA4 IMPG2 ZNF513